2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 143

Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 762

Aquaporin-4 Immunoglobulin G Antibody Positive Neuromyelitis Optica Spectrum Disorder and Systemic Autoimmune Diseases Overlap Syndrome: A Single Center Experience

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 554

Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 724

Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis?

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 257

Argentine Registry of Patients with Fibromyalgia

Fibromyalgia and Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 372

Arterial Involvement in Erdheim-Chester Disease: A Retrospective Cohort Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 494

Arterial Wall Inflammation Declines after 6 Months of Anti-Inflammatory Therapy with Methotrexate and/or Adalimumab in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 35

Arthritis and Atherosclerosis in KRN Ag7 Mice Involve Distinct Inflammatory Cell Populations and Are Independent of CCR2

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 439

Articular Cartilage from Osteoarthritis Patients Shows Extracellular Matrix Remodeling over the Course of Treatment with Sprifermin (Recombinant human fibroblast growth factor 18)

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 703

Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 718

Assessing Dyspnea in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 440

Assessing Inappropriate Pain Management in Adults with Hip or Knee Osteoarthritis Treated with Different Opioid Intensity Regimens: Results from a Retrospective Database Analysis

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 156

Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 315

Assessing the Value of Whole Body Magnetic Resonance Imaging As to Clinical Examination to Predict Remission and Relapse in Early Peripheral Spondyloarthritis

Imaging of Rheumatic Diseases Poster I: MRI

9:00AM-11:00AM: Abstract Number: 825

Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study

Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

«Previous Page
1
…
3
4
5
6
7
…
67
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].